Aim: The neuroinflammatory hypothesis suggests that proinflammatory cytokines or the immune system may play a role in the etiopathogenesis of depression. COVID-19 affects older people the most because their immune systems are weakened. In this study, we aimed to examine the effect of using antidepressant use on mortality in patients infected with COVID-19. Material and Methods: Our study was developed as a retrospective examination of unique central patient records. In our study, the diagnosis of COVID-19 diagnostics (U07.3) was between the ICD-10 classification (U07.3) and the diagnosis of depressive emotional state disorders (F31, F32, F33, F34) and patients with the diagnosis of COVID-19 confirmed by the test result were included. Results: Considering the relationship between the use of antidepressants and mortality in COVID-19 patients, it was seen that the mortality rate was significantly lower in those using antidepressants (p <0.05). The presence of chronic disease was found to be significantly associated with mortality in COVID-19. The mortality rates of patients with chronic diseases were found to be higher (p <0.01). Discussion: In our study, we found that antidepressants did not have any superiority over each other in terms of mortality in COVID-19 patients.However, when all anti depressants were evaluated in our study, we observed that drug use had a positive effect on statistically significant mortality (p <0.05). More enlightening results will emerge in larger case series.
Is it possible that antidepressants protect against COVID-19? Anti-depresants and covid